Two Blood Monocytic Biomarkers (CCL15 and p21) Combined with the Mini-Mental State Examination Discriminate Alzheimer’s Disease Patients from Healthy Subjects
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder. In AD, monocytes migrate across the blood-brain barrier and differentiate into microglia, are linked to inflammatory responses and display age-dependent decreases in telomere lengths. Methods: Six monocyte-specific chemokines and the (telomere-associated) tumor suppressor proteins p53 and p21 were determined by multiplex immunoassay in plasma and monocyte extracts of patients with AD or mild cognitive impairment, and levels were compared between patients and controls (without cognitive impairment). Results: CCL15 (macrophage inflammatory protein-1δ), CXCL9 (monokine-induced by interferon-γ) and p21 levels were decreased in monocytes of AD patients compared with controls. Conclusion: The combination of monocytic CCL15 and p21 together with the Mini-Mental State Examination enables to differentiate AD patients from controls with high specificity and sensitivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The levels of p16INK4a have been reported to be elevated in neurons from AD patients [194,198,199,200], as well as in neurons from AD mouse models [195].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [200]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Telomeres shorten during ageing of human fibroblasts
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Current concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Wyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Tsou, C.-L., Peters, W., Si, Y., Slaymaker, S., Aslanian, A. M., Weisberg, S. P., Mack, M., & Charo, I. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29919 · Cited by 1,152
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048
Cited by
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
CXCR3 ligands in disease and therapy
Van Raemdonck, K., Van den Steen, P. E., Liekens, S., Van Damme, J., & Struyf, S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.11.009 · Cited by 310
“as opposing reports regarding CXCL9 plasma levels in AD patients have been published [246,247].”
ResultStuart, M. J., & Baune, B. T. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.02.001 · Cited by 259
Marksteiner, J., Blasko, I., Kemmler, G., Koal, T., & Humpel, C. (2018) · Metabolomics · doi:10.1007/s11306-017-1297-5 · Cited by 159
“Indeed, we have shown in our lab, that the tumor suppressor p21 is markedly reduced in monocytes of AD patients (Hochstrasser et al. 2011).”
BackgroundSelf-citationSystemic immune system alterations in early stages of Alzheimer's disease
Zhang, R., Miller, R. G., Madison, C., Jin, X., Honrada, R., Harris, W., Katz, J., Forshew, D. A., & McGrath, M. S. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.01.002 · Cited by 121
“Apart from brain-specific changes, an increasing number of studies in AD have reported alterations in systemic immune responses including changes in lymphocyte and macrophage distribution and activation, the presence of autoantibodies, or abnormal inflammatory factors and cytokine production (Kusdra et al., 2000; Gali…”
Zhou, F., Sun, Y., Xie, X., & Zhao, Y. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01254-1 · Cited by 74
“Other investigations, on the other hand, have reported null relationships of chemokine levels with AD [26, 27] or MCI [28, 29].”
BackgroundRole of platelets in neurodegenerative diseases: a universal pathophysiology
Behari, M., & Shrivastava, M. (2013) · International Journal of Neuroscience · doi:10.3109/00207454.2012.751534 · Cited by 68
“The search for a suitable diagnostic marker has been extended to the peripheral tissues, and for this reason, blood biomarkers are in the focus of research [79].”
BackgroundMartin-Ruiz, C., Williams-Gray, C. H., Yarnall, A. J., Boucher, J. J., Lawson, R. A., Wijeyekoon, R. S., Barker, R. A., Kolenda, C., Parker, C., Burn, D. J., et al. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191724 · Cited by 58
“Furthermore, in AD patients monocytic p21 protein 573 levels were decreased compared to control individu574 als [59].”
BackgroundInflammatory Markers in Mild Cognitive Impairment: A Meta-Analysis
Saleem, M., Herrmann, N., Swardfager, W., Eisen, R., & Lanctôt, K. L. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150042 · Cited by 64
“[ 30 ] M C P1 12 /1 1 50 .”
Plagg, B., Ehrlich, D., Kniewallner, K. M., Marksteiner, J., & Humpel, C. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150710114256 · Cited by 61
“protein-1 (MCP-1), macrophage inflammatory protein 1α (MIP1α/CCL3; only humans), macrophage inflammatory protein 2 (MIP2) and tumor necrosis factor α (TNFα)) Thermo Scientific SearchLight Protein Array Technology (THP Medical Products, Vienna) was used as described by us [43].”
MethodSelf-citationGuan, L., Crasta, K., & Maier, A. B. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101634 · Cited by 57
“13 whereas p53 protein in monocytes was undetectable (Hochstrasser et al., 2011).”
BackgroundWu, C.-Y., Bawa, K. K., Ouk, M., Leung, N., Yu, D., Lanctôt, K. L., Herrmann, N., Pakosh, M., & Swardfager, W. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101130 · Cited by 51
Cerebrospinal fluid and blood biomarkers in Alzheimer’s disease
Humpel, C. (2011) · World Journal of Psychiatry · doi:10.5498/wjp.v1.i1.8 · Cited by 50
Self-citationT lymphocyte senescence is attenuated in Parkinson’s disease
Kouli, A., Jensen, M. P., Papastavrou, V., Scott, K. M., Kolenda, C., Parker, C., Solim, I. H., Camacho, M., Martin-Ruiz, C. M., & Williams‐Gray, C. H. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02287-9 · Cited by 48
“Blood-based expression of these markers has not been well-studied in the context of neurodegeneration, although p21 expression in monocytes has been reported to be lower in Alzheimer’s disease [41], and we have previously found evidence of reduced p21 expression in total leukocytes in early PD, as well as an associati…”
BackgroundLi, Y., Yang, Y., Zhao, A., Luo, N., Niu, M., Kang, W., Xie, A., Lu, H., Chen, L., & Liu, J. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02481-3 · Cited by 47
“showed that in monocytes, CCL15 levels were significantly lower in AD patients than in healthy subjects, but they were increased in AD patient plasma [29].”
BackgroundMonocytes in the Peripheral Clearance of Amyloid-β and Alzheimer’s Disease
Guo, H., Zhao, Z., Zhang, R., Chen, P., Zhang, X., Cheng, F., & Gou, X. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-181177 · Cited by 36
“The levels of CCL15, CXCL9 and p21 in peripheral blood monocytes were also decreased in AD patients [83].”
Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer’s Disease
Robinson, R. A. S., Amin, B., & Guest, P. C. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-52479-5_2 · Cited by 32
Haskins, M., Jones, T. E., Lu, Q., & Bareiss, S. K. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.11.002 · Cited by 33
Platelet-Derived Secreted Amyloid-Precursor Protein-β as a Marker for Diagnosing Alzheimer’s Disease
Marksteiner, J., & Humpel, C. (2013) · Current Neurovascular Research · doi:10.2174/15672026113109990022 · Cited by 29
Self-citationChemokines in patients with Alzheimer's disease: A meta-analysis
Wang, H., Zong, Y., Zhu, L., Wang, W., & Han, Y. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1047810 · Cited by 21
“In clinical trials, compared with the control group, the protein level of CCL15 in monocytes of AD patients was down-regulated significantly (Hochstrasser et al., 2011).”
BackgroundIncreased inflammation in BA21 brain tissue from African Americans with Alzheimer’s disease
Ferguson, S. A., Varma, V., Sloper, D. T., Panos, J., & Sarkar, S. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-019-00512-2 · Cited by 19
Chen, Y.-C., Chiu, Y., Lin, C., Hsu, W., Wu, J.-L., Huang, C.-H., Lin, C.-W., Yao, C., Huang, H.-J., Lo, Y., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180643 · Cited by 18
Early Detection and Treatment of Patients with Alzheimer’s Disease: Future Perspectives
Guest, F. L. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-05542-4_15 · Cited by 19
Zhang, T., Luu, M. D. A., Dolga, A. M., Eisel, U. L. M., & Schmidt, M. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1207280 · Cited by 21
“In AD patients and mouse models, elevated senescent markers, p16, p21, p53 and senescence associated β-Galactosidase (SA-β-Gal) were observed (Arendt et al., 1996; Arendt et al., 1998; McShea et al., 1997; Lüth et al., 2000; Engidawork et al., 2001; Hochstrasser et al., 2011; Esteras et al., 2012; Esteras et al., 2013…”
BackgroundNie, J., Fang, Y., Chen, Y., Aisikeer, A., Qiu, Q., Zhao, L., Liu, X., Sun, L., Li, Y., Zhong, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.803633 · Cited by 15
“Significant elevations in plasma CCL15 levels in AD have been reported by others; however, the data showed no changes in CCL15 in mild cognitive impairment (38).”
ResultVastrad, B. M., & Vastrad, C. M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.06.442918 · Cited by 13
“Previous investigation demonstrates that RGS4 [83], CXCL11 [84], EGR1 [85], CALB1 [86], BDNF (brain derived neurotrophic factor) [87], TERT (telomerase reverse transcriptase) [88], NEFL (neurofilament light) [89], SNAP25 [90], RPH3A [91], NRN1 [92], SYT1 [93], GRIN2B [94], AVP (arginine vasopressin) [95], VSNL1 [96],…”
P21 Gene Variation and Late-Onset Alzheimer’s Disease in the Italian Population
Scacchi, R., Gambina, G., Moretto, G., & Corbo, R. M. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000345788 · Cited by 10
Alzheimer’s disease: a step closer to understanding type 3 diabetes in African Americans
Ferguson, S. A., Panos, J., Sloper, D. T., Varma, V., & Sarkar, S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00754-z · Cited by 6
A Novel Method to Identify Differential Pathways in Hippocampus Alzheimer’s Disease
Liu, C.-H., & Liu, L. (2017) · Medical Science Monitor · doi:10.12659/msm.900929 · Cited by 1
Induction of astrocytes senescence by Plasmodium infection : role in cerebral malaria
Hellani, F. (2022) · theses.fr (ABES) · doi:10.70675/c2a869d4zae4fz44d6zbbd2z03500c51bea0
Vastrad, B. M., & Vastrad, C. M. (2025) · Genome Instability & Disease · doi:10.1007/s42764-025-00147-x
“…et al., 2017), FCGR2B (Costa et al., 2020), MMP9 (Kaminari et al., 2018), CNN2 (Gonzalez & Brandan, 2019), C5AR1 (Hernandez et al., 2017), CCL15 (Hochstrasser et al., 2011), RBPMS (RNA binding protein, mRNA processing factor) (Lim et al., 2020), TBX2 (Reinhardt et al., 2019), FPR2 (Iribarren et…”
Neuro-axonale Pathologie bei Multipler Sklerose
Hochstrasser, T. (2023) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.31302
Self-citationLi, Y., Yang, Y., Zhao, A., Luo, N., Niu, M., Kang, W., 谢安木, Lu, H., Chen, L., & Liu, J. (2022) · Figshare · doi:10.6084/m9.figshare.19863065
Metadata
- Authors
- Hochstrasser, T., Marksteiner, J., Defrancesco, M., Deisenhammer, E. A., Kemmler, G., & Humpel, C.
- Affiliations
- Innsbruck Medical University (AT)
- Corresponding author
- Humpel, Christian
- Venue
- Dementia and Geriatric Cognitive Disorders Extra
- Publisher
- S. Karger AG
- Published
- 2011-10-06
- Volume
- 1
- Issue
- 1
- Pages
- 297-309
- ISSN
- 1664-5464 (ISSN-L)
- PMC
- PMC3235941
- OpenAlex
- W2087886914
- Cited by
- 31
- References
- 55
- Citations by year
- 2025: 1 · 2023: 3 · 2022: 4 · 2021: 3 · 2020: 1 · 2019: 5 · 2018: 1 · 2017: 3 · 2015: 3 · 2014: 2 · 2013: 4
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/3.0/ (vor)
- creativecommons.org/licenses/by-nc/3.0/ (tdm)
- Locations
- Dementia and Geriatric Cognitive Disorders Extra (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Austrian Science Fund
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, blood biomarkers, monocytes, CCL15, p21, CXCL9, chemokines, telomere length, p53, Mini-Mental State Examination, mild cognitive impairment, plasma biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.